Zobrazeno 1 - 10
of 821
pro vyhledávání: '"Estrogen receptor-positive"'
Autor:
Takayuki Kobayashi, Meiko Nishimura, Mari Hosonaga, Rika Kizawa, Saori Kawai, Yosuke Aoyama, Yukinori Ozaki, Ippei Fukada, Fumikata Hara, Toshimi Takano, Takayuki Ueno
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Absolute lymphocyte count (ALC) is a predictive and prognostic factor for various tumor types, including breast cancer. Palbociclib is a CDK4/6 inhibitor widely used for the treatment of metastatic estrogen receptor (ER)-positive,
Externí odkaz:
https://doaj.org/article/1e6f7c53792d4145b42f0e111048dcb5
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 1189-1204 (2024)
Jiafeng Lu,1,* Zhaoyan Li,2,* Xingjing Liu,2 Bin Xu,1 Weiyu Zhang2 1Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Department of Traditional Chinese Medicine, Ruijin Hospital, S
Externí odkaz:
https://doaj.org/article/dbfae30de7a340babeea13b20f45fddb
Autor:
Jui-Hung Tsai, Kuo-Ting Lee
Publikováno v:
Journal of Cancer Research and Practice, Vol 11, Iss 2, Pp 73-76 (2024)
Background: CDK 4/6 inhibitor (CDK4/6i) is the first-line therapeutic drug to treat ER-positive (ER+) HER2-negative (HER2 -) metastatic breast cancer (MBC) now. We have three CDK4/6i: Palbociclib, Ribociclib, and Abemaciclib. In the long-term follow-
Externí odkaz:
https://doaj.org/article/1700d3ee54334235ac3fe666406fb733
Autor:
Luca Scafuri, Carlo Buonerba, Vincenzo Di Lauro, Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Antonio Marra, Paolo Tarantino, Dario Trapani, Mario Giuliano, Grazia Arpino, Giuseppe Curigliano, Giuseppe Di Lorenzo
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 363-373 (2024)
Abstract Background Breast cancer presents diverse molecular subtypes affecting treatment strategies. Human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer poses a challenge due to limited targeted therapi
Externí odkaz:
https://doaj.org/article/2b162889839543f080aaba98a06a8db9
Autor:
Sherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, Fábio Franke, Michelino de Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Andrés Cardona, Özgür Özyilkan, Flavia Morales-Vàsquez, Ciara Metcalfe, Marc Hafner, Eleonora Restuccia, Joyce O’Shaughnessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. Bi-directional
Externí odkaz:
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
Publikováno v:
Journal of Ovarian Research, Vol 16, Iss 1, Pp 1-12 (2023)
Abstract Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by ovarian cysts, high androgen levels, and irregular menstruation. The causality between PCOS and breast cancer (BC) has been widely discussed as they share a significa
Externí odkaz:
https://doaj.org/article/a11a74db374444db9a8cc14182fc09dc
Autor:
Wang, Fenhua †, 1, Ren, Fang †, 1, Qian, Jian 1, Xu, Yunxiao 1, Wu, Jiayi 2, Zong, Yu 3, ⁎, Gu, Xidong 4, ⁎⁎
Publikováno v:
In Clinical Breast Cancer December 2024
Publikováno v:
BMC Medical Genomics, Vol 16, Iss 1, Pp 1-19 (2023)
Abstract Background The largest group of patients with breast cancer are estrogen receptor-positive (ER+) type. The estrogen receptor acts as a transcription factor and triggers cell proliferation and differentiation. Hence, investigating ER-DNA inte
Externí odkaz:
https://doaj.org/article/4e53024e3bb34b8990f097c40e86f931
Autor:
E.D. Chiru, C. Grasic Kuhar, A. Oseledchyk, A. Schötzau, M.J. Gonzalez, C. Kurzeder, M. Vetter
Publikováno v:
Translational Oncology, Vol 36, Iss , Pp 101724- (2023)
Background: In early luminal breast cancer, the Oncotype DX® Recurrence Score (RS) prognostic and predictive value with regards to chemotherapy (CHT) application benefit has been broadly validated. In older patients its value has not been deeply add
Externí odkaz:
https://doaj.org/article/929e7802051543bda43908d25b18983b
Autor:
Hui‐Ping Hsu, Pei‐Yi Chu, Tsung‐Ming Chang, Kuo‐Wei Huang, Wen‐Chun Hung, Shih Sheng Jiang, Hui‐You Lin, Hui‐Jen Tsai
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1588-1601 (2023)
Abstract Background Tumor cells may aberrantly express metabolic enzymes to adapt to their environment for survival and growth. Targeting cancer‐specific metabolic enzymes is a potential therapeutic strategy. Phosphoenolpyruvate carboxykinase (PEPC
Externí odkaz:
https://doaj.org/article/95aa146bb8eb4a7c8ac27962dfcfb6c6